Takeda Pharmaceutical Co., Ltd. (TAK)
21.43
+0.31
(+1.47%)
USD |
NYSE |
Nov 13, 16:00
21.43
0.00 (0.00%)
Pre-Market: 19:59
Takeda Pharmaceutical Enterprise Value : 94.93B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 94.93B |
| November 12, 2026 | 93.94B |
| November 11, 2026 | 93.04B |
| November 10, 2026 | 93.33B |
| November 09, 2026 | 93.84B |
| November 06, 2026 | 93.62B |
| November 05, 2026 | 94.16B |
| November 04, 2026 | 93.75B |
| November 03, 2026 | 92.76B |
| November 02, 2026 | 93.14B |
| October 30, 2026 | 93.27B |
| October 29, 2026 | 90.39B |
| October 28, 2026 | 90.84B |
| October 27, 2026 | 91.22B |
| October 26, 2026 | 91.73B |
| October 23, 2026 | 91.13B |
| October 22, 2026 | 91.51B |
| October 21, 2026 | 90.14B |
| October 20, 2026 | 90.62B |
| October 19, 2026 | 89.11B |
| October 16, 2026 | 89.31B |
| October 15, 2026 | 88.60B |
| October 14, 2026 | 87.20B |
| October 13, 2026 | 85.63B |
| October 12, 2026 | 86.14B |
| Date | Value |
|---|---|
| October 09, 2026 | 86.30B |
| October 08, 2026 | 85.63B |
| October 07, 2026 | 85.15B |
| October 06, 2026 | 84.29B |
| October 05, 2026 | 83.36B |
| October 02, 2026 | 83.52B |
| October 01, 2026 | 83.52B |
| September 30, 2026 | 84.58B |
| September 29, 2026 | 86.07B |
| September 28, 2026 | 87.30B |
| September 25, 2026 | 87.17B |
| September 24, 2026 | 86.32B |
| September 23, 2026 | 87.02B |
| September 22, 2026 | 87.46B |
| September 21, 2026 | 87.27B |
| September 18, 2026 | 87.33B |
| September 17, 2026 | 87.77B |
| September 16, 2026 | 86.48B |
| September 15, 2026 | 86.67B |
| September 14, 2026 | 86.35B |
| September 11, 2026 | 85.28B |
| September 10, 2026 | 84.80B |
| September 09, 2026 | 85.12B |
| September 08, 2026 | 85.47B |
| September 04, 2026 | 85.88B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Sanofi | 126.67B |
| Dr. Reddy's Laboratories Ltd. | 12.27B |
| Astellas Pharma, Inc. | 31.40B |
| Daiichi Sankyo Co., Ltd. | 31.74B |
| Eisai Co., Ltd. | 8.931B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.209B |
| Revenue (Quarterly) | 7.454B |
| Total Expenses (Quarterly) | 6.246B |
| EPS Diluted (Quarterly) | 0.3736 |
| Gross Profit Margin (Quarterly) | 57.91% |
| Profit Margin (Quarterly) | 16.21% |
| Earnings Yield | 0.29% |
| Operating Earnings Yield | 7.78% |
| Normalized Earnings Yield | 1.024 |